1. What are the main clinical applications of HPV molecular testing? 

HPV molecular testing is commonly used in several cervical screening and follow-up settings. 

Application 1: Primary cervical cancer screening

HPV DNA testing can be used as a primary screening method in eligible populations under established national or regional screening programs. The purpose is to identify high-risk HPV infections that may be associated with an increased risk of cervical precancer. For this application, laboratories need an assay with appropriate high-risk HPV coverage, validated sample compatibility and reliable result interpretation. 

Application 2: Triage after abnormal cervical cytology

When a Pap test identifies certain abnormalities, HPV testing may provide additional information for clinical risk assessment. For example, a patient with atypical squamous cells of undetermined significance (ASC-US)may undergo reflex high-risk HPV testing, depending on the applicable clinical guidelines. The HPV result can help clinicians determine the appropriate follow-up pathway. 

Application 3: HPV16/18 genotype differentiation

HPV16 and HPV18 are particularly important high-risk genotypes. Identifying these types separately can provide additional risk information when evaluating a positive HPV screening result. 

Application 4: Follow-up after previous cervical abnormalities or treatment

Patients with a history of cervical precancer treatment may require HPV-based surveillance according to clinical guidelines. 

In this setting, laboratories should use an appropriately validated assay and follow the recommended testing interval and clinical management pathway. 

2. Why is HPV testing important when cervical cytology results are abnormal? 

Cervical cytology and HPV molecular testing provide different types of information. 

A Pap test examines cervical cells for morphological abnormalities, whereas an HPV molecular assay detects the presence of targeted viral nucleic acid. 

Consider a patient whose cytology result is ASC-US. This finding indicates that some cervical cells appear slightly abnormal, but the result alone does not establish the underlying cause. 

Depending on the patient's age, screening history and local guidelines, high-risk HPV testing may be used to support further risk assessment. 

The possible laboratory findings include: 

- High-risk HPV not detected. 

- High-risk HPV detected. 

- HPV16 detected. 

- HPV18 detected. 

- Other covered high-risk HPV types detected. 

These results provide different levels of information and can help clinicians determine whether additional evaluation is appropriate. 

This is one reason why laboratories may prefer HPV assays that offer partial genotyping rather than only a pooled positive or negative result. 

3. Why do clinical laboratories need separate HPV16 and HPV18 detection? 

HPV16 and HPV18 are among the most clinically important carcinogenic HPV types. 

According to the 2019 ASCCP risk-based management guidelines, HPV16- or HPV18-positive results may warrant additional evaluation even when cervical cytology is negative. 

For example: 

A patient undergoing routine cervical screening receives a negative cytology result but tests positive for HPV18. 

Although no cytological abnormality is identified, the HPV18 result provides important additional risk information. Under the ASCCP guidelines, colposcopy is recommended for HPV18-positive patients with negative cytology. 

This illustrates why genotype-specific information can matter in clinical screening pathways. 

For laboratories, the practical requirement is to determine whether an assay can: 

- Detect high-risk HPV types as a group. 

- Separately identify HPV16 and HPV18. 

- Provide additional individual genotype results when required. 

SINGUWAY HPV001 is designed to detect 15 high-risk HPV types, with HPV16 and HPV18 classified separately and the remaining covered types detected as a combined group. 

This detection configuration is relevant to laboratories that require HPV16/18 differentiation alongside broader high-risk HPV detection. 

4. What is the difference between testing for persistent HPV infection and a single positive HPV result? 

A positive HPV result indicates that the targeted HPV nucleic acid was detected in the tested specimen. 

However, a single positive result does not establish persistent infection. 

Persistent infection is assessed through repeated testing over time, interpreted together with the patient's previous screening results and clinical history. 

For example:

- A patient receives a positive high-risk HPV result during an initial screening. 

- The patient undergoes follow-up according to the recommended clinical interval. 

- A subsequent test again detects high-risk HPV. 

- The clinician evaluates the repeated results, genotype information and other clinical findings. 

This is why consistent assay performance, appropriate follow-up intervals and reliable result interpretation are important in cervical screening programs. 

Laboratories should avoid interpreting a single positive HPV test as evidence of persistent infection or cervical cancer. 

5. Which HPV genotyping information is useful in different clinical situations? 

Different clinical applications require different levels of genotype information. 

The most appropriate assay depends on the intended clinical use and the local screening algorithm. A larger genotype panel is not automatically necessary for every screening program. 

 6. How does nucleic acid extraction affect HPV PCR testing? 

HPV PCR testing generally requires appropriate sample preparation before amplification. 

For extraction-based workflows, the laboratory needs to consider: 

1. Sample homogenization and preparation. 

2. Cell lysis and nucleic acid release. 

3. DNA binding and purification. 

4. Washing and elution. 

5. Transfer of purified nucleic acid into the PCR reaction. 

Inadequate extraction, PCR inhibitors or poor specimen quality may affect the final result. 

For laboratories processing multiple cervical specimens, automated nucleic acid extraction systems can help standardize sample processing and reduce repetitive manual operations. 

SINGUWAY provides magnetic bead-based nucleic acid extraction systems and compatible extraction reagents. The appropriate extraction method must be confirmed for the specific HPV assay and specimen type. 

7. What should laboratories consider when implementing HPV testing with real-time PCR? 

A suitable real-time PCR system should meet the technical requirements of the HPV assay. 

Important considerations include: 

- Required fluorescence channels.

- Reaction volume. 

- PCR cycling conditions. 

- Optical detection capability. 

- Software configuration. 

- Internal control interpretation. 

- Laboratory testing capacity. 

For example, SINGUWAY's AccuRa-32 is a 32-sample real-time PCR system with four fluorescence channels. 

It can be evaluated as part of a molecular diagnostic laboratory setup, subject to confirmation of compatibility with the specific HPV assay, fluorescence dyes and reaction protocol. 

The complete workflow should be verified before routine testing. 

8. What quality control measures are important in HPV molecular testing?

Reliable HPV testing requires quality control throughout the entire process. 

Laboratories should consider: 

Specimen quality control----Ensure that samples are collected, transported and stored according to the assay requirements. 

Extraction quality control----Monitor nucleic acid preparation and potential contamination during sample processing. 

PCR controls---- Use the positive, negative and internal controls specified in the kit instructions. 

Contamination prevention----Separate pre-amplification and post-amplification activities and follow appropriate laboratory contamination-control procedures. 

Result review----Interpret amplification curves, control results and genotype signals according to the manufacturer's instructions. 

These measures support consistent laboratory operations and help identify invalid or potentially unreliable results. 

9. How can laboratories build an HPV molecular testing solution? 

An HPV testing solution should be designed around the laboratory's clinical service and expected sample volume. 

For example: 

Scenario A: A laboratory introducing high-risk HPV screening

The laboratory may prioritize a suitable high-risk HPV assay, validated cervical specimen preparation and a compatible real-time PCR platform. 

Scenario B: A laboratory requiring HPV16/18 differentiation

The laboratory should evaluate assays that separately identify HPV16 and HPV18, such as SINGUWAY HPV001. 

Scenario C: A laboratory requiring more detailed genotype information

The laboratory can evaluate a genotype-specific assay such as SINGUWAY HPV002, taking its four-reaction-group configuration into account. 

Scenario D: A laboratory expanding its molecular diagnostic department

The laboratory may need to assess HPV reagents, nucleic acid extraction systems, extraction reagents, real-time PCR instruments and routine quality control as a coordinated workflow. 

These are different implementation scenarios, and the final product configuration should be confirmed against the laboratory's intended use and assay compatibility requirements. 

10. How can IVD distributors develop an HPV molecular diagnostics product portfolio? 

For distributors, HPV molecular diagnostics can be positioned as part of a broader women's health and molecular diagnostics portfolio. Potential customers include: 

- Hospital clinical laboratories. 

- Independent diagnostic laboratories. 

- Women's health diagnostic centers. 

- Molecular pathology laboratories. 

- Public and private screening programs. 

Before introducing HPV products, distributors should assess local cervical screening policies, testing demand, competing products, registration requirements and laboratory infrastructure. 

A portfolio that includes different HPV detection configurations, extraction systems and PCR platforms may provide more flexibility when responding to different laboratory requirements. 

SINGUWAY works with international IVD partners and laboratories to discuss molecular diagnostic products, technical documentation and potential workflow configurations. 

Looking for HPV PCR detection products or a molecular diagnostic solution for your laboratory?

Contact SINGUWAY to discuss HPV assay configurations, technical documentation and potential laboratory workflow solutions. Email: sales@singuway.com